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Introduction: Ventilator-induced lung injury (VILI) contributes to morbidity and mortality in acute respiratory
distress syndrome (ARDS). Particularly pre-injured lungs are susceptible to VILI despite protective ventilation. In a
previous study, the endogenous peptide adrenomedullin (AM) protected murine lungs from VILI. We hypothesized
that mechanical ventilation (MV) contributes to lung injury and sepsis in pneumonia, and that AM may reduce lung
injury and multiple organ failure in ventilated mice with pneumococcal pneumonia.
Methods: We analyzed in mice the impact of MV in established pneumonia on lung injury, inflammation, bacterial
burden, hemodynamics and extrapulmonary organ injury, and assessed the therapeutic potential of AM by starting
treatment at intubation.
Results: In pneumococcal pneumonia, MV increased lung permeability, and worsened lung mechanics and oxygenation
failure. MV dramatically increased lung and blood cytokines but not lung leukocyte counts in pneumonia. MV induced
systemic leukocytopenia and liver, gut and kidney injury in mice with pneumonia. Lung and blood bacterial burden was
not affected by MV pneumonia and MV increased lung AM expression, whereas receptor activity modifying protein (RAMP)
1–3 expression was increased in pneumonia and reduced by MV. Infusion of AM protected against MV-induced lung injury
(66% reduction of pulmonary permeability p< 0.01; prevention of pulmonary restriction) and against VILI-induced liver and
gut injury in pneumonia (91% reduction of AST levels p< 0.05, 96% reduction of alanine aminotransaminase (ALT) levels
p < 0.05, abrogation of histopathological changes and parenchymal apoptosis in liver and gut).
Conclusions: MV paved the way for the progression of pneumonia towards ARDS and sepsis by aggravating
lung injury and systemic hyperinflammation leading to liver, kidney and gut injury. AM may be a promising
therapeutic option to protect against development of lung injury, sepsis and extrapulmonary organ injury in
mechanically ventilated individuals with severe pneumonia.Introduction
In acute respiratory failure, mechanical ventilation (MV)
is a life-saving intervention without alternatives, but MV
may cause ventilator-induced lung injury (VILI). Since
clinical trials have been highlighting the impact of VILI on
acute respiratory distress syndrome (ARDS) mortality [1],
lung-protective ventilation has been widely implemented* Correspondence: martin.witzenrath@charite.de
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distribution, and reproduction in any mediumin clinical practice. However, clinical and experimental
studies provide evidence that VILI occurs despite low tidal
volume ventilation and that particularly preinjured lungs
are susceptible for the development of VILI [2,3].
Lung injury worsened in ventilated mice upon infec-
tion with Staphylococcus aureus even under protective
ventilation strategies [4], which is intriguing as pneu-
monia is the leading cause of ARDS and sepsis [1,5].
However a major limitation of this and other studies
was that mice were infected after initiation of MV
[4,6,7]. Experimental studies investigating the impactCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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immune system is already activated and lung mechan-
ics are changed due to pneumonic infiltrates – would
be of particular clinical relevance.
VILI has been linked to multiple organ failure [8,9]. Im-
proved understanding of the impact of VILI on the pro-
gression of pneumonia towards sepsis with its detrimental
complications is desirable. Thus, we implemented a new
second-hit model of established pneumococcal pneumo-
nia and MV.
While the risk of ARDS development may be reduced
by lowering tidal volumes, MV with low tidal volumes
still seems to aggravate lung injury and further tidal vol-
ume reduction is limited by hypercapnia, which aggra-
vates acidosis. Adjuvant pharmacotherapies in addition
to protective ventilation are thus needed to further limit
VILI. Adrenomedullin (AM), an endogenous 52-amino-
acid peptide belonging to the calcitonin gene-related pep-
tide family, is crucial for regulation of endothelial barrier
integrity [10]. AM binds to the calcitonin receptor-like re-
ceptor (CRLR) assembled with receptor activity modifying
protein (RAMP)-1 to RAMP3, thereby raising intracellular
cAMP levels in endothelial cells and reducing myosin light
chain phosphorylation. Consequently, interendothelial gap
formation is prevented [10-12]. Exogenous AM reduced
pulmonary hyperpermeability in experimental acute lung
injury and sepsis [13,14], and we identified AM as being
protective against VILI and associated kidney injury in
previously healthy mice by stabilizing endothelial barrier
function and microcirculation [13]. These and other stud-
ies gave rise to a recent positive opinion from the Com-
mittee for Orphan Medicinal Products of the European
Medicines Agency (EMA), recommending the granting of
the development of AM as an orphan drug for the treat-
ment of acute lung injury/ARDS (EMA/COMP/104704/
2010 to SH). However, although AM proved to be benefi-
cial in healthy lungs subjected to VILI, evidence is lacking
for a protective effect of AM during MV of individuals
with severe pneumonia. Clinical trials with AM are cur-
rently being planned, so additional preclinical evidence is
desirable.
We therefore conducted the current study to decipher
the contribution of VILI and underlying mechanisms to
the progression of ARDS, sepsis and multiple organ dys-
function syndrome in pneumonia, to test the therapeutic
impact of AM in the treatment of VILI-driven lung in-
jury in pneumonia, and to investigate potential protect-




Animal experiments were approved by the animal ethics
committee of Charité-Universitätsmedizin Berlin and localgovernmental authorities (Landesamt für Gesundheit und
Soziales Berlin).
Mice
Female C57Bl/6 mice (8 to 10 weeks; 18 to 20 g; Charles
River, Sulzfeld, Germany) were used.
Pneumococcal pneumonia
Streptococcus pneumoniae (serotype 3, strain NCTC7978)
was grown to mid log phase. Mice were anesthetized by
intraperitoneal ketamine (1.6 mg) and xylazine (0.5 mg)
and were transnasally inoculated with 5× 106 colony-
forming units of S. pneumoniae diluted in 20 μl sterile
phosphate-buffered saline (10 μl into each nostril) as
described previously [15]. Noninfected mice were anesthe-
tized and transnasally inoculated with 20 μl phosphate-
buffered saline.
Mechanical ventilation and adrenomedullin treatment
Twenty-four hours after infection when severe pneumo-
nia had devolved, mice were subjected to MV as de-
scribed previously [16,17]. Mice were anesthetized by
intraperitoneal injections of fentanyl (75 μg/kg), midazo-
lam (1.5 mg/kg) and medetomedin (0.75 mg/kg). Repeti-
tively, fentanyl (16 μg/kg), midazolam (0.33 mg/kg) and
medetomedin (0.16 mg/kg) were supplied via an intra-
peritoneal catheter when required to guarantee adequate
anesthesia during the observation period. Body temperature
was maintained at 37°C by a body temperature-controlled
heating pad. Tracheotomy and intubation was performed,
and a carotid artery catheter was placed for blood
pressure monitoring and infusion of NaCl 0.9% con-
taining 100 mmol/l HCO3
− (350 μl/hour). No additional
fluid support was provided in any experiment. A urin-
ary catheter was inserted. The tidal volume, respiratory
rate, airway pressure, and urine output were monitored
(Pulmodyn; Hugo-Sachs-Electronics, March-Hugstetten,
Germany).
After preparation, a recruitment maneuver was per-
formed (airway pressure 35 cmH2O for 5 seconds) and
mice were ventilated for 6 hours with a tidal volume of
12 ml/kg, a respiratory rate of 120 breaths/minute, and a
positive end-expiratory pressure of 2 cmH2O (MiniVent;
Hugo-Sachs-Electronics). A second recruitment maneu-
ver was performed 5 minutes before termination of the
experiment. All mice survived the protocol. At termin-
ation of the experiments, mice were sacrificed by exsan-
guination via the carotid artery catheter. Blood samples
were analyzed for partial arterial pressure of oxygen by
blood gas analyzer (ABL-800; Radiometer, Copenhagen,
Denmark). The P/F ratio was calculated as partial ar-
terial pressure of oxygen/fraction of inspired oxygen.
Nonventilated mice served as controls. Murine AM
(0.05 mg/kg/hour; Phoenix, Burlingame, CA, USA) was
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ing with onset of ventilation. The dosage was proven to be
effective without causing relevant hemodynamic changes
in mice [13].
Quantitative real-time polymerase chain reaction
Lungs were flushed and snap-frozen in liquid nitrogen.
Total RNA was isolated from the lungs using the RNeasy
mini kit (Qiagen, Hilden, Germany) according to the man-
ufacturer’s instructions. To remove genomic DNA con-
tamination, isolated RNA samples were treated with 1 U
DNase/μg RNA (Invitrogen, Karlsruhe, Germany) for 15
minutes at 37°C. One microgram of total RNA was used
in a 20 μl reaction to synthesize cDNA using Superscript
H– reverse transcriptase (200 U/μg RNA; Invitrogen) and
oligo dTs as primers. Reverse transcription reaction was
carried out for 50 minutes at 42°C. Quantitative real-time
polymerase chain reaction (qRT-PCR) was performed
using the I-Cycler IQ detection system (Bio-Rad, Munich,
Germany) in combination with the IQ SYBR Green
Real-Time PCR Supermix (Bio-Rad). The polymerase
chain reaction conditions included initial denaturation
in one cycle of 10 minutes at 95°C followed by 40 cy-
cles of 20 seconds at 95°C, 20 seconds at 60°C, and
20 seconds at 72°C. The relative expressions were cal-
culated as:
2– ΔCTð Þ  1=mean control 2– ΔCTð Þ
 
where ΔCT (CT; Threshold Cycle) is calculated as:
ΔCT ¼ CTgene of interest–CThousekeeping gene
Primer sequences are provided in Additional file 1.
Regulation of CRLR and RAMP 1, 2 and 3 mRNA in un-
infected, spontaneously breathing mice and uninfected,
mechanically ventilated mice has been published previ-
ously [16].
Lung permeability
Human serum albumin (HSA) was injected intraven-
ously 90 min prior to the end of the experiment. After
ligation of the left stem bronchus bronchoalveolar lavage
(BAL) was performed twice with 400 μl PBS each. From
each BAL portion, 250 μl were pooled and BAL and
plasma HSA concentration was determined by enzyme-
linked immunosorbent assay. Permeability was assessed
by calculating the HSA BAL/plasma ratio as described
[17].
Hypoxic vasoconstriction in precision-cut lung slices
Precision-cut lung slices (PCLS) were prepared as de-
scribed previously [18]. Briefly, mice were killed by cer-
vical dislocation and the airways were filled with 1.5%
low melting point agarose. After solidification of theagarose, the lungs were cut into 200 μm thick slices. The
agarose was removed by incubation of the PCLS in phe-
nol red-free minimal essential medium continuously
gassed with 21% oxygen, 5% carbon dioxide (CO2), 74%
nitrogen for at least 2 hours at 37°C.
To analyze the vasoreactivity of individual cross-sectioned
intra-acinar arteries (minimal inner diameter up to 40 μm),
the PCLS were transferred into a flow-through superfusion
chamber (Hugo-Sachs-Elektronik). At the beginning of
each experiment the capability of the vessel to contract
in response to the thromboxane analogue U46619 and
to dilate after application of the nitric oxide donor so-
dium nitroprusside was checked. After washing out
these drugs with normoxic gassed phenol red-free
minimal essential medium (21% oxygen, 5% CO2, 74%
nitrogen), the PCLS were incubated with hypoxic
gassed medium (1% oxygen, 5% CO2, 94% nitrogen; 0.7
ml/minute). After 15 minutes, 500 nM murine AM
was added to the hypoxic medium. After a second
washout, the PCLS were again challenged with U46619
in the presence of 500 nM AM when the hypoxic incu-
bation was performed in the presence of AM or solv-
ent, respectively.
Pictures of the artery were taken every 2 minutes using
an inverted microscope mounted on the superfusion
chamber. Changes in the luminal area of the vessels
were evaluated by manually lining the inner boundaries.
The luminal area at the beginning of hypoxia was de-
fined as 100% and vasoreactivity was expressed as a
relative decrease or increase of this area. Only the
values (mean ± standard error of the mean) obtained
for the hypoxic incubation followed by the incubation
in hypoxic medium ± AM, the second washout phase
and the final challenge with U44619 ± AM are given
below.Leukocytes in lung tissue, bronchoalveolar lavage fluid
and blood
The lungs were flushed. The left lung was digested in
RPMI containing collagenase and DNAse for 1 hour.
Leukocytes were extracted by meshing the lung tissue
through a cell strainer (100 μm) and differentiated by
flow cytometry according to their side-scatter/forward-
scatter properties and CD45, Gr-1 and F4-80 expression
(FACSCalibur, BD, Heidelberg, Germany). Blood leuko-
cytes were quantified and differentiated by flow cytometry
using TruCount-Tubes (BD, Heidelberg, Germany) accord-
ing to cellular side-scatter/forward-scatter properties and
CD45, Gr-1 and CD3 expression.Quantification of cytokines
Cytokines were quantified from total protein of flushed
homogenized left lungs and from plasma samples by the
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CA, USA).Bacterial burden
Serial dilutions of BALF, spleen homogenate and blood
were plated on blood agar and incubated at 37°C under
5% CO2 for 24 hours to count colony-forming units.Creatinine, aspartate transaminase, alanine transaminase
and neutrophil gelatinase-associated lipocalin
Creatinine, aspartate transaminase and alanine transamin-
ase plasma levels were quantified by routine laboratory
tests. Neutrophil gelatinase-associated lipocalin levels in
urine samples collected over the last 2 hours of the MV
period were measured by enzyme-linked immunosorbent
assay (BioPorto, Gentofte, Denmark).Histology
Immunolabeling for AM was performed by overnight incu-
bation at room temperature with previously characterized
antibodies, including double-labeling with biotinylated rat
monoclonal anti-CD31 (1 μg/ml, clone MEC 13.3; BD
Biosciences, Heidelberg, Germany), an endothelial marker
[19]. Secondary reagents, each applied for 1 hour, were Cy3-
conjugated goat anti-human IgG F(ab)2 (1:500; Dianova,
Hamburg, Germany), Cy3-conjugated donkey anti-rabbit IgG
(1:2,000; Dianova), and fluorescein isothiocyanate-conjugated
streptavidin (1:500; Sigma, Deisenhofen, Germany). Tis-
sue sections depicting all groups were processed simul-
taneously and images were taken at the same exposure
time.
For analysis of apoptosis, staining against cleaved caspase-
3 (CC3) was used as an indicator of apoptotic cell death as
described previously [20]. In brief, paraffin sections were in-
cubated overnight with a polyclonal anti-cleaved caspase-3
antibody (Asp175, 1:50; Cell Signaling Technology, Frankfurt,
Germany). A secondary antibody was added and 3,3′-
diaminobenzidine served as chromogen. Apoptotic cells
appeared with a brown color. The sections were counter-
stained with hemalaun. In each procedure, sections of thy-
mus tissue served as positive control because apoptosis is
a constant event in this organ.Data analyses
Data are expressed as mean ± standard error of the mean.
For comparison between groups, the Mann–Whitney U test
was used. P < 0.05 was considered statistically significant.
For the comparison of experiments using PCLS, the area
under the curve of each phase of every single experiment
was calculated. Comparison between groups for each
phase was performed again by Mann–Whitney U test,
and P < 0.05 was considered statistically significant.Results
Pulmonary expression of adrenomedullin and its receptor
complexes
Pneumonia and MV each increased pulmonary AM mRNA
expression (Figure 1A). Immunofluorescent staining of AM
in pulmonary tissue revealed that in naïve lungs AM pro-
tein was located mainly, although not exclusively, in
macrophages and in pulmonary endothelium, which
was confirmed by double staining of AM and the
endothelial marker CD31 (see Additional file 2). In line
with increased AM mRNA expression after MV, we
observed a MV-induced increase of parenchymal AM
protein. Furthermore, pneumonic infiltrates were posi-
tive for AM immunostaining, with recruited leukocytes
displaying marked immunoreactivity (Figure 1B). AM
specificity of the employed antibody was validated in
pre-absorption experiments (see Additional file 3). Regula-
tion of the AM receptor components CRLR and RAMP1
to RAMP3 was investigated by qRT-PCR analyses. As re-
ported previously [16], MV alone had no impact on CRLR
or RAMP1 and RAMP2 expression while RAMP3 was
downregulated. Pneumonia resulted in an increase of
RAMP1 to RAMP3 expression, while MV markedly re-
duced mRNA levels of RAMP1 to RAMP3 in pneumo-
nia (Figure 1C). Notably, treatment with AM did not
alter expression of AM, CRLR or RAMP1 to RAMP3
in pneumonia and subsequent MV (see Additional file 4).
Regulation of the AM receptor components CRLR and
RAMP1 to RAMP3 was investigated by qRT-PCR ana-
lyses. As reported previously [21], MV alone had no im-
pact on CRLR or RAMP1 and RAMP2 expression
while RAMP3 was downregulated. Pneumonia resulted
in an increase of RAMP1 to RAMP3 expression, while
MV markedly reduced mRNA levels of RAMP1 to RAMP3
in pneumonia (Figure 1C). Notably, treatment with AM did
not alter expression of AM, CRLR or RAMP1 to RAMP3 in
pneumonia and subsequent MV (see Additional file 4).
Mechanical ventilation exacerbated lung injury in
pneumonia: protection by adrenomedullin
Pneumonia as well as MV each increased pulmonary vascu-
lar permeability. AM reduced MV-evoked lung permeability.
Notably, when mice with pneumonia were subjected to MV
a further dramatic increase in lung permeability was ob-
served, which was almost completely avoided by AM treat-
ment starting with onset of MV (Figure 2A).
Under volume-controlled MV, an increase in the peak
inspiratory pressure reflects a decrease of lung compli-
ance, which is mostly due to lung edema in the current
model. While pneumonia and MV alone had no impact
on peak inspiratory pressure as compared with healthy
mice, MV in infected mice led to a significant increase of
peak inspiratory pressure after 6 hours of MV, which was
almost completely impeded by AM treatment (Figure 2B).















































































































MV + S.p.NV + S.p.
Figure 1 Regulation of adrenomedullin and its receptor complexes due to pneumonia and mechanical ventilation. Pneumococcal
pneumonia (S.p.) was induced 24 hours before mechanical ventilation (MV) was performed for 6 hours. Nonventilated (NV) mice were sacrificed
30 hours after infection. Regulation of (A) adrenomedullin (AM) and (C) its receptor components calcitonin receptor-like receptor (CRLR) and
receptor activating modifying protein (RAMP)- 1, 2 and 3 were quantified by quantitative real-time polymerase chain reaction in lung homogenate
(*P< 0.05; **P< 0.01, n= 5). Note that the receptor expression data for the NV and MV groups without infection have been published previously
[21]. (B) Immunofluorescence analysis of lung tissue. AM-immunolabeling was enhanced in MV mice compared with NV mice. In pneumonic
infiltrates, leukocytes showed intense AM-immunolabeling. Representative images from five animals per group are shown.
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pneumonia or MV alone, the combination of pneumonia
and MV led towards severe deterioration of oxygenation.
Although AM reduced lung injury in mechanically venti-
lated mice, AM did not ameliorate the deterioration of
oxygenation (Figure 2C). Histology performed 24 hours
post infection confirmed severe necrotizing broncho-
pneumonia affecting 40 to 60% of the lung tissue. Changes
due to MV could not be dissected from the already preva-
lent severe alteration in the lungs due to pneumonia (see
Additional file 5). With regard to the missing improvement
1in oxygenation despite barrier-stabilizing properties of
AM and preserved lung mechanics in the pneumonia +
MV group, we hypothesized that vasodilatory properties in
the lung of AM might have been counteracting the reduc-
tion of lung injury by increasing ventilation/perfusion mis-
match. Indeed, vasoconstriction due to hypoxia or the
thromboxane agonist U46619 was significantly reduced by
AM in murine PCLS (Figure 2D).
Mechanical ventilation aggravated pulmonary
inflammation in pneumonia
The concentrations of the cytokines interleukin (IL)-1β,
IL-6, keratinocyte-derived cytokine (KC) and IL-10 in lung
homogenate were increased by pneumonia and, to a lesser
extent, by MV. In pneumonia, MV led to a further dramaticincrease of IL-1β, IL-6 and KC, while IL-10 levels remained
unaffected. AM treatment had no impact on pulmonary
cytokine levels (Figure 3A).
In pneumonia and in MV, pulmonary polymorpho-
nuclear neutrophils (PMN) and Gr-1high monocytes were
increased. A combination of MV and pneumonia did not
further increase PMN and Gr-1high monocytes. Notably,
AM decreased pulmonary Gr-1high monocyte recruit-
ment in uninfected mice subjected to MV, but not in
mice with pneumonia subjected to MV (Figure 3B).Mechanical ventilation had no impact on pulmonary
bacterial outgrowth and development of bacteremia in
pneumonia
Blood and spleen homogenate bacterial counts were
assessed in BALF. MV and AM each had no impact
on pulmonary bacterial burden, bacteremia or dissem-
ination to the spleen in pneumonia (Figure 4).Mechanical ventilation aggravated systemic
hyperinflammation in pneumonia
Pneumonia and MV each increased plasma IL-6, KC and
IL-10 levels. In pneumonia, MV caused a further in-
crease of systemic cytokine levels. AM treatment had no
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Figure 2 Adrenomedullin protected mice with pneumonia against mechanical ventilation-induced lung injury. Pneumococcal
pneumonia (S.p.) was induced 24 hours before mechanical ventilation (MV) was performed for 6 hours. Continuous adrenomedullin (AM) infusion
(0.05 mg/kg/hour) started with the onset of MV. Nonventilated (NV) mice were sacrificed 30 hours after infection. (A) Human serum albumin
(HSA) was injected 90 minutes prior to termination of the experiment and the HSA concentration (cHSA) in plasma and in bronchoalveolar
lavage (BAL) was determined. An increased HSA BAL/plasma ratio indicated enhanced lung permeability (*P < 0.05, **P < 0.01; NV, n = 5; NV + S.p.,
n = 4; MV, n = 5; MV + AM, n = 4; MV + S.p., n = 7; MV + S.p. + AM, n = 5). (B) Peak inspiratory pressure (PIP) was analyzed after 6 hours of MV
following a final recruitment maneuver (**P < 0.01; NV and NV + S.p., n = 5; all other groups, n = 8 each). (C) Arterial oxygen partial pressure was
determined at the end of the experiment and the P/F ratio was calculated (**P < 0.01; NV and NV + S.p., n = 5; MV, n = 6; MV + AM, n = 7; MV +
S.p., n = 5; MV + S.p. + AM, n = 8). (D) In precision cut lung slices, vasoconstriction was induced by hypoxia (hypoxic pulmonary vasoconstriction)
and by the thromboxane receptor agonist U46619 in the presence or absence of AM (0.5 μM). The luminal areas of single intra-acinar pulmonary
arteries were continuously analyzed by planimetry and the area under the curve (AUC) was calculated for each experiment. Significant AUC
differences between the two groups were evident under hypoxia, during the wash out phase and after U46619 challenge (ns, not significant;
**P < 0.01, ***P < 0.001; n = 10 each).
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Pneumonia increased circulating neutrophils and mono-
cytes while lymphocyte counts remained unaffected. MV
reduced lymphocytes but had no effect on other leukocyte
populations. In infected mice subjected to MV, blood
leukocyte counts were significantly reduced compared
with nonventilated mice with pneumonia, and lympho-
cyte counts dropped significantly below those observed
in naïve mice. Besides almost restoring lymphocyte
levels in uninfected mice subjected to MV, AM treat-
ment had no significant impact on blood leukocyte counts
(Figure 5B).
Adrenomedullin protected mice with pneumonia against
MV-related organ failure
Aspartate aminotransferase and alanine aminotransami-
nase levels were not altered by pneumonia or MV, whereas
MV in pneumonia dramatically increased transaminaselevels, which was almost completely avoided by AM
(Figure 6A). We observed extended liver injury dis-
played by necrotic areas and induction of hepatic apop-
tosis exclusively in the pneumonia +MV group, which was
undetectable under AM treatment. More specifically,
periportal rings of CC3+ cells were highly prominent
(Figure 6B) in four out of six livers from the pneumo-
nia + MV group and showed weaker prominence in
two livers. In the liver sections of the pneumonia +
MV + AM group only small, single islets of CC3+ cells
were found. In all other groups, CC3+ cells were rare
(0 to 5 per section). In ileum sections, an enhanced
number of CC3+ cells was almost exclusively observed
in the pneumonia + MV group, indicating tissue injury
that was abolished by AM treatment (Figure 6C).
In the pneumonia +MV group increased urine neutro-
phil gelatinase-associated lipocalin levels were measured
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Figure 3 Mechanical ventilation induced exacerbation of pulmonary inflammation in pneumonia independently of leukocyte counts.
Pneumococcal pneumonia (S.p.) was induced 24 hours before mechanical ventilation (MV) was performed for 6 hours. Continuous adrenomedullin
(AM) infusion (0.05 mg/kg/hour) started with the onset of MV. Nonventilated mice were sacrificed 30 hours after infection. (A) Cytokine levels
of interleukin (IL)-1β, IL-6, keratinocyte-derived cytokine (KC) and IL-10 were measured in lung homogenate. **P < 0.01; n = 6 each. (B) Leukocytes were































































Figure 4 Mechanical ventilation has no impact on lung bacterial outgrowth and systemic bacterial dissemination. Pneumococcal
pneumonia (S.p.) was induced 24 hours before mechanical ventilation (MV) was performed for 6 hours. Continuous adrenomedullin (AM) infusion
(0.05 mg/kg/hour) started with the onset of MV. Nonventilated mice were sacrificed 30 hours after infection. Serial dilutions of bronchoalveolar
lavage (BAL) fluid, spleen homogenate and blood were plated on agar, and colony-forming units (CFU) were counted after 24 hours of incubation
(n = 5 to 7).
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Figure 5 Mechanical ventilation induced systemic hyperinflammation in pneumonia. Pneumococcal pneumonia (S.p.) was induced 24
hours before mechanical ventilation (MV) was performed for 6 hours. Continuous adrenomedullin (AM) infusion (0.05 mg/kg/hour) started with
the onset of MV. Nonventilated mice were sacrificed 30 hours after infection. (A) Cytokine levels of IL-6, keratinocyte-derived cytokine (KC) and
IL-10 were measured in blood plasma **P < 0.01; n = 5 or 6 each). (B) Whole blood leukocytes were quantified and differentiated by flow cytometry
(*P < 0.05, **P < 0.01; n = 5 each). PMN, polymorphonuclear neutrophils.
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son with naïve mice and a trend towards further in-
creased creatinine levels in the pneumonia +MV group
was observed (see Figure S5B in Additional file 6). Urine
output was not altered (see Figure S5C in Additional file
6). These findings suggest early tubular injury due to
MV in pneumonia unaffected by AM.
Notably, hematocrit in the pneumonia +MV +AM
group was lower compared with the pneumonia +MV
group, suggesting intravasal plasma conservation due to
systemic stabilization of vascular barrier function by AM
(Figure 6D).
Discussion
In the current experimental study, MV induced lung in-
jury in pneumonia and promoted sepsis and multiple
organ injury. AM infusion protected against lung edema
and liver and gut injury without interfering with inflam-
matory host responses.For this study, we launched a novel experimental
model to display the relevant interaction of VILI and
pre-established pneumonia regarding lung injury, sys-
temic inflammation and multiple organ dysfunction.
VILI was induced by ventilating mice for 6 hours with
moderately injurious tidal volumes of 12 ml/kg. Al-
though 6 ml/kg is recommended for lung-protective
ventilation in humans, the currently applied settings
meet the requirements for protective ventilation in mice.
The tidal volume of 12 ml/kg with a respiratory rate of
120 breaths/minute induced only a minor increase in
lung permeability and inflammation, while having no im-
pact on hepatic or renal injury in healthy mice [17].
Lower tidal volumes would require higher respiratory
rates to ensure CO2 removal, which independently con-
tributed to VILI [21] and was therefore avoided.
We first investigated the expression of AM and its re-
ceptor complexes and observed pulmonary upregulation
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Figure 6 Adrenomedullin protected against mechanical ventilation-induced liver and gut injury in mice with pneumonia. Pneumococcal
pneumonia (S.p.) was induced 24 hours before mechanical ventilation (MV) was performed for 6 hours. Continuous adrenomedullin (AM) infusion
(0.05 mg/kg/hour) started with the onset of MV. Nonventilated (NV) mice were sacrificed 30 hours after infection. (A) Liver transaminases (alanine
aminotransaminase (ALT), aspartate aminotransferase (AST)) were quantified in blood plasma (*P < 0.05, ***P < 0.001; n = 6 to 8 each). Liver and
ileum sections were stained for cleaved caspase 3 (CC3) and counterstained with hemalaun. (B) In the MV + S.p. group, liver lobular necrosis
(white arrow) surrounded by rings of CC3+ apoptotic cells (black arrow) developed, which was absent under AM treatment (MV + S.p. + AM).
(C) Apoptotic CC3+ cells were observed in ileum sections of the MV + S.p. group, and to a lesser extent in the MV + S.p. + AM group.
Representative images from six animals per group are shown. (D) Hematocrit (Hct) was reduced following AM treatment in ventilated mice
with pneumonia (MV + S.p. + AM) as compared with sham-treated mice (MV + S.p.) (*P < 0.05; n = 5 or 6 each).
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macrophages, while AM expression in pneumonia could
mainly be attributed to invading leukocytes forming pul-
monary infiltrates. However, MV tended to downregu-
late overall AM expression in pneumonia. AM binds toCRLR assembled with RAMPs, mainly RAMP2 and
RAMP3 [10]. Expression of all three RAMPs was up-
regulated in pneumonia, and reduced by additional
MV. In summary, reduced expression of RAMP1 to
RAMP3 under MV in pneumonia was observed,
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due to reduced endogenous AM function. Notably,
AM therapy had no influence on the expression of
AM, CRLR or RAMP1 to RAMP3.
We reported previously that exogenous AM protected
mice against VILI even in the context of hyperoxia and
delayed onset of treatment [13]. However, the applied
models did not reproduce the clinically relevant situation
when patients with respiratory failure due to pneumonia
need MV. In the current study, pneumonia-induced lung in-
jury was exacerbated by MV as displayed by increased per-
meability and edema and decreased oxygenation capacity.
These changes could not be attributed to further pulmonary
leukocyte recruitment due to MV, but were paralleled by a
dramatic increase of pulmonary inflammatory cytokines.
Some studies reported immunomodulating effects of AM
offering protection against lipopolysaccharide-induced sys-
temic hyperinflammation and lung injury or against polymi-
crobial sepsis in mice [22,23]. In line with these studies,
pulmonary Gr-1high monocytes, which have specifically been
linked to VILI [24], were reduced by AM in mechanically
ventilated mice without pneumonia. However, AM did not
alter cytokine levels, overall leukocyte counts or Gr-1high
monocytes in the lungs of mechanically ventilated mice
with pneumonia, suggesting that protection by AM
was not primarily mediated by immunomodulation in
this study but targets a central mechanism downstream of
harmful hyperinflammation.
Taking the current and previous findings into account,
stabilization of endothelial integrity was most probably
the main mechanism of the observed protective AM ef-
fect [11,12,14,25,26]. From the clinical point of view it is
preferable to stabilize lung barrier function independ-
ently from the inflammatory state because hyperinflamma-
tion is frequently established when it comes to intubation
in pneumonia and sepsis, because hyperinflammation may
override anti-inflammatory properties of pharmacologic
therapies, and because pharmacologic immunosuppression
may pave the way for secondary infections [27]. Further,
while disturbance of microcirculation is a hallmark of
organ failure during septic shock, AM stabilized microcir-
culation in inflammation [26,28]. Although not directly evi-
denced by the current study, this protective function of
AM possibly contributed to the observed effects.
Oxygenation was not improved in AM-treated mice
despite marked reduction of permeability and edema.
This contradictory finding may be explained by vasodila-
tory AM effects. More specifically, vasoconstriction caused
by the thromboxane agonist U44619 or hypoxia were di-
minished by AM in lung tissue slices. Although direct evi-
dence is not provided, it is tempting to speculate that
reduction of pulmonary vascular resistance by AM resulted
in increased shunt perfusion, probably masking improve-
ment of oxygenation capacity following reduction of edemaformation in AM-treated mice. Importantly, AM treatment
did not result in deterioration of mean systemic arterial
blood pressure or microcirculatory impairment as assessed
by blood lactate.
Cyclic stretch of alveolar epithelial cells in MV has been
observed to enhance bacterial growth and bacteremia,
thereby augmenting the development of sepsis and organ
failure [6,23,29,30]. However, this mainly holds true for
Gram-negative bacteria, while bacterial growth and trans-
location of Gram-positive bacteria such as S. aureus was
not influenced by cyclic stretch in vitro or by MV in vivo
[4,30]. Further, Gram-positive S. pneumoniae actively in-
vades lung tissue, so that MV-associated bacterial trans-
location may be of inferior relevance particularly in
pneumococcal pneumonia [31]. In the current study,
all infected mice were bacteriemic and MV did not im-
pact pulmonary S. pneumoniae outgrowth or bacteremia.
Nevertheless, infected mice subjected to MV developed
severe sepsis, whereas spontaneously breathing mice did
not. Severe sepsis was displayed by dramatically increased
blood cytokines, leukopenia and hepatic, renal and intes-
tinal injury, which, most notably, could not be attributed
to hemodynamic deterioration.
AM protected against hepatic and intestinal injury in
VILI-driven sepsis. These findings support previous stud-
ies in which AM protected from liver or gut injury in
staphylococcal α-toxin induced shock, in polymicrobial
sepsis or in gut ischemia and reperfusion [14,22,32].
Again, in the majority of studies, tissue-protective ef-
fects of AM have been attributed to anti-inflammatory
properties, whereas anti-inflammatory effects of AM
were not detected in the current study. Apoptosis may
be crucial for the development of organ failure in sep-
sis, and AM holds anti-apoptotic properties [33]. How-
ever, whether protection from apoptosis observed here
and elsewhere is the mechanism of or a consequence
of other yet unknown underlying AM functions remains
unclear. The lower hematocrit in AM-treated mice cur-
rently observed indicated intravascular plasma conserva-
tion due to systemic vascular barrier protection by AM,
confirming previous studies demonstrating barrier protec-
tion in the liver, ileum and kidney as a central beneficial
mechanism of AM in shock [14]. Taken together, AM pro-
tected against hepatic and intestinal injury accompanied
by anti-apoptotic and barrier protective effects without
modulating hyperinflammation in pneumonia-associated
VILI-driven sepsis. Further characterization of this potent
protective AM function downstream of injurious hyperin-
flammation warrants further investigation.
One limitation of this study was that AM treatment
could not be investigated in nonventilated mice be-
cause this requires vascular catheterization for con-
tinuous infusion due to the very short half-life of AM.
This catheterization is not feasible in awake mice, and
Figure 7 Mechanical ventilation drives pneumococcal pneumonia into lung injury and sepsis: protection by adrenomedullin.
Ventilator-induced lung injury (VILI) led to substantial aggravation of previously established severe pneumonia resulting in acute respiratory failure,
which was accompanied by elevation of pulmonary cytokine levels independent from leukocyte recruitment or bacterial replication in the lung.
Adrenomedullin (AM) protected against development of lung injury without having anti-inflammatory or antimicrobial functions, probably by mediating
vascular barrier protection and stabilization of microcirculation. VILI induced the development of sepsis and related multiple organ failure, which was avoided
by AM. ARDS, acute respiratory distress syndrome.
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supine position for instrumentation probably results in
hypoventilation, thereby provoking major bias to the
sensitive readout performed here.
Conclusion
This study provides evidence that MV with moderate
tidal volumes aggravates lung injury and promotes pro-
gression of sepsis and multiple organ failure in pneumo-
coccal pneumonia. Exogenous AM, which has gained
orphan drug status from the EMA for treatment of
ARDS recently, protected against MV-induced lung in-
jury and sepsis-related organ failure without suppres-
sion of the host immune response (Figure 7). These
data further encourage current efforts to evaluate AM
as adjuvant therapy for VILI in addition to protective
ventilation strategies and for sepsis-related organ fail-
ure in clinical trials.
Key messages
 In mice with pneumococcal pneumonia, MV evoked
lung injury and led to the development of sepsis
with multiple organ injury independent of bacterial
translocation.
 AM infusion protected against lung injury and
extrapulmonary organ failure in this condition. Being acknowledged as an orphan drug for ARDS
treatment by the EMA, AM therapy may be a
potential future adjuvant pharmacotherapy in
patients with severe pneumonia subjected to MV.
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